A Real-World Registry Evaluation Visual Performance And Patient Satisfaction Outcomes Of A Novel Wavefront-Shaping Presbyopia-Correcting Toric Iol

To report Real World outcomes on visual acuity, patient satisfaction, spectacle independence, visual disturbances and refractive outcomes in patients implanted with a wavefront-shaping presbyopia correcting Toric IOL, AcrySof® IQ Vivity™ Toric (models DFT215, DFT315, DFT415, DFT515 and DFT515).

Multicenter, ambispective registry study conducted in Europe, the UK, Australia and New Zealand evaluating the performance of bilaterally implanted AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.

This is a sub-analysis of the second interim dataset, where 256 subjects were implanted with the toric version of the AcrySof IQ Vivity IOL at least in one eye. After approximately 3 months follow-up per local clinical practice standards, subjects undergone visual performance assessments of visual acuity at distance, intermediate (66 cm) and near (40 cm) distances. Refractive residual error, subject satisfaction, and spectacle independence recorded via validated questionnaires as well as visual disturbances were reported.

In this ongoing trial, we have so far recruited 256 subjects implanted with at least one eye with AcrySof IQ Vivity Toric. The interim analysis shows binocular mean (SD) (logMAR) UDVA 0.022 (0.107); UIVA 0.086 (0.116) and UNVA 0.252 (0.159). 83% of all eyes had ≤ 0.50 D of manifest refractive cylinder after surgery. 88.0% of subjects reported rarely or never wearing glasses at arm’s length and 90.9% are satisfied with their sight. No halos, glare and starbursts were reported by 91.4%, 90.9% and 95.5%, respectively. 

In this assessment of subjects implanted with AcrySof IQ Vivity Toric IOL, we observed good distance, intermediate and functional near vision. Subjects also reported high levels of satisfaction with their vision, good levels of spectacle independence and very low levels of visual disturbances.